Table 4. Determination of Phenobarbital in Different Pharmaceutical Formulation Samplesa.
| amount
found, ± SD* |
||||||
|---|---|---|---|---|---|---|
| sample | labeled amount | potentiometry | recovery, % | HPLC method | recovery, % | F-test |
| Doloran inf. (Pharco Co., Egypt) (supplement) | 150 mg | 147.9 ± 0.4 | 98.6 | 151.2 ± 0.1 | 100.8 | 4.43 |
| Vegaskine ped. (Alex Co., Egypt) (supplement) | 150 mg | 153.2 ± 0.8 | 102.1 | 149.3 ± 0.2 | 99.5 | 6.20 |
| Migrainil (Nile Co., Egypt) (tablet) | 10 mg/tablet | 9.8 ± 0.6 | 98 | 10.1 ± 0.2 | 101 | 3.46 |
| Sominal (Alex Co., Egypt) (tablet) | 15 mg/tablet | 14.3 ± 1.1 | 95.3 | 14.9 ± 0.1 | 99.3 | 3.21 |
| Minophylline (Memphis Pharm. Co., Egypt) (syrup) | 66 mg/100 mL | 64.2 ± 2.1 | 97.2 | 65.3 ± 0.6 | 98.9 | 2.45 |
| Sominal (Alex Co., Egypt) (ampul) | 40 mg/mL | 40.9 ± 0.4 | 102.2 | 39.8 ± 0.3 | 99.5 | 2.32 |
a
± SD* (standard deviation for an average of five measurements).